Pages that link to "Q37518057"

The following pages link to Assessing treatment response to interferon-β: is there a role for MRI? (Q37518057):

Displaying 27 items.

• Newer therapies for multiple sclerosis (Q26779900) (← links)
• Optimizing therapy early in multiple sclerosis: An evidence-based view (Q26783070) (← links)
• Is it time to target no evident disease activity (NEDA) in multiple sclerosis? (Q26801550) (← links)
• Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach (Q28080043) (← links)
• Outcome Measures in Clinical Trials for Multiple Sclerosis. (Q31160866) (← links)
• Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations. (Q33692568) (← links)
• Magnetic resonance imaging in multiple sclerosis--patients' experiences, information interests and responses to an education programme (Q34557520) (← links)
• Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod (Q36097847) (← links)
• MRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: a retrospective analysis of a community based cohort (Q36141526) (← links)
• Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis (Q36247618) (← links)
• Predictors of disease activity in 857 patients with MS treated with interferon beta-1b (Q36265324) (← links)
• Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression. (Q36352813) (← links)
• Defining Disease Activity and Response to Therapy in MS. (Q36357501) (← links)
• Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients (Q38654791) (← links)
• The future of multiple sclerosis treatments. (Q38808485) (← links)
• Treatment decisions in multiple sclerosis - insights from real-world observational studies. (Q39022643) (← links)
• Decreased interferon-β induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis. (Q39130808) (← links)
• Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study (Q39900185) (← links)
• Predictive value of early brain atrophy on response in patients treated with interferon β (Q41197913) (← links)
• Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a. (Q48215414) (← links)
• Improved Lesion Detection by Using Axial T2-Weighted MRI with Full Spinal Cord Coverage in Multiple Sclerosis. (Q48266807) (← links)
• Any evident MRI T2-lesion activity should guide change of therapy in multiple sclerosis--yes (Q48359293) (← links)
• Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis: no. (Q48378176) (← links)
• Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis (Q52141693) (← links)
• Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. (Q53069773) (← links)
• Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. (Q53841734) (← links)
• Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study. (Q55379969) (← links)